683 Capital Management’s BioAtla BCAB Stock Holding History

683 Capital Management’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-372	Closed	-$153K	–	306
2022 Q4	$153K	Buy	+372	New	+$154K	0.01%	218

Other funds holding BCAB

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

683 Capital Management's BCAB Position: Q1 2023 in Review

683 Capital Management sold out of BioAtla (BCAB) in Q1 2023, closing a stake of 372 shares — an estimated $153K sold.

683 Capital Management first reported a position in BCAB in Q4 2022 and held it in 1 quarter. The position peaked at $153K in Q4 2022. 79 funds tracked by Wall St. Rank hold BCAB as of Q1 2023.

683 Capital Management reported no remaining BioAtla position as of Q1 2023 after selling out during the quarter.
683 Capital Management sold 372 BioAtla shares in Q1 2023, an estimated $153K.
683 Capital Management first reported a position in BioAtla in Q4 2022 and held it in 1 quarter.
683 Capital Management's BioAtla position peaked at $153K in Q4 2022.
79 funds tracked by Wall St. Rank held BioAtla as of Q1 2023.

Based on 683 Capital Management's 13F filing for Q1 2023, filed 15 May 2023.